

**Supplementary Table S1**

<b>Characteristics</b>	<b>Untreated</b>	<b>Sensitive</b>	<b>Resistant</b>
<b>Number of patients</b>	24	8	11
<b>Number of specimens</b>	26	9	15
<b>Median age (range)</b>	64.5 (18-86)	58 (34-66)	59 (45-80)
<b>Male</b>	10	5	9
<b>Location</b>			
Gastric	19	2	2
Small Bowel	4	4	2
Liver	3	0	2
Peritoneum	0	2	6
Other*	0	1	3
<b>Tyrosine kinase inhibitor (most recent)</b>			
Imatinib	Not applicable	8	6
Sunitinib	Not applicable	0	2
Multiple	Not applicable	0	1
Other	Not applicable	0	2
<b>Median cumulative duration of treatment (months)</b>	Not applicable	6.5 (4-11.6)	45 (1.1-143.4)
<b>Mutation of tumor specimen</b>			
<i>KIT</i> exon 9	0	1	0
<i>KIT</i> exon 11	12	5	9
<i>KIT</i> exon 17	0	0	3
PDGFRA	0	0	2
WT	5	0	1
Unavailable	9	3	0

\*Other locations were rectal (sensitive) and abdominal wall, diaphragm, and pleura (resistant).